McKesson Corporation vs Ishares Msci Thailand Etf — how do they compare? McKesson Corporation trades at $935.88 (market cap $108.46B), while Ishares Msci Thailand Etf trades at $71.67 (market cap $426.83M). The key difference: McKesson Corporation is far larger — about 254.1× Ishares Msci Thailand Etf's market cap, and McKesson Corporation pays a 0.4% dividend while Ishares Msci Thailand Etf pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Ishares Msci Thailand Etf for 65 Days on average.
| MCK | THD | |
|---|---|---|
Market Cap | $108.46B | $426.83M |
Volume | 712,607 | 82,409 |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $75.06 |
52-Week Low | $725.17 | $57.86 |
Typical Hold Time | 74 Days | 65 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
THD trades at $71.80, down 0.15% with a bearish technical outlook as moving averages signal selling pressure. Short interest surged 90.6% in September 2026, indicating growing skepticism. The ETF has delivered strong 38% returns over the past year, outperforming ASEAN peers, but faces headwinds from potential profit-taking in AI-exposed holdings like Delta Electronics.
The outlook is cautious given elevated short interest and technical weakness. While THD benefits from Thailand's AI hardware exposure, concentration risk and regional capital outflows pose challenges. Investors should weigh strong historical performance against near-term sentiment pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →